WHI-P258

CAS No. 21561-09-1

WHI-P258( WHI-P258 | WHI-P 258 | WHI-P-258 | WHIP 258 )

Catalog No. M13440 CAS No. 21561-09-1

WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 32 In Stock
5MG 28 In Stock
10MG 46 In Stock
25MG 88 In Stock
50MG 137 In Stock
100MG 233 In Stock
200MG 341 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WHI-P258
  • Note
    Research use only, not for human use.
  • Brief Description
    WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.
  • Description
    WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK binding negative control in the development of new therapeutics.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WHI-P258 | WHI-P 258 | WHI-P-258 | WHIP 258
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR| JAK3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    21561-09-1
  • Formula Weight
    281.31
  • Molecular Formula
    C16H15N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: <1.2mg/mL
  • SMILES
    COC1=CC2=NC=NC(NC3=CC=CC=C3)=C2C=C1OC
  • Chemical Name
    6,7-Dimethoxy-N-phenylquinazolin-4-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Fry DW, et al. Science. 1994, 265(5175), 1093-1095.
molnova catalog
related products
  • AG-825

    AG-825(Tyrphostin C15) is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.

  • Beta-Hydroxyisovaler...

    Beta-Hydroxyisovalerylshikonin is an inhibitor of protein-tyrosine kinases such as v-Src and EGFR, and has been shown to induce apoptosis in several human tumor cell lines. Beta-Hydroxyisovalerylshikonin significantly decreased viability of HCT116 cells (IC50 values = 30.9 μg/mL).

  • Vandetanib

    Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability.